Actively Recruiting
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-05-11
5000
Participants Needed
7
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will determine the biochemical and genetic causes of inherited immune diseases affecting lymphocyte homeostasis. Lymphocytes are a type of white blood cell that fights infections. Normally, the body keeps a precise balance in which lymphocyte growth is matched by lymphocyte death. People with constantly enlarged lymph nodes or spleen, along with autoimmune disease, immunodeficiency, lymphoma, or other immune problems affecting lymphocytes may have an abnormality of the immune system in the cell growth and cell death processes that regulate lymphocyte homeostasis. Patients who have, or are suspected of having, an inherited lymphocyte homeostasis or programmed cell death susceptibility syndrome may be eligible for this study. Relatives of patients are also included. Participants' (patients and relatives) medical records are reviewed and blood samples are drawn for studies to identify genes involved in immune disorders. Tissues that have been removed from patients for medical reasons, such as biopsied tissues, may be examined for tissue and DNA studies. Relatives are studied to determine if some of them may have a very mild form of lymphocyte homeostasis disorder. Patients who have an immune problem that the researchers wish to study further will be invited to donate additional blood samples at irregular intervals (at least once a year) and to provide an update of their medical records at the same time. ...
CONDITIONS
Official Title
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients known or suspected to have an inherited immune cell homeostasis, programmed cell death susceptibility syndrome, lymphocyte developmental block, or defective immune cell effector functions
- Patients with suspected disease if the investigator agrees there is a high index of suspicion
- Blood relatives of enrolled patients
- No limits on age, sex, race, or disability
You will not qualify if you...
- Severely debilitated health status
- Poor venous access preventing adequate specimen collection
- Infants weighing less than 3 kg due to blood draw volume limits
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
2
University of Michigan
Ann Arbor, Michigan, United States, 48109-0624
Actively Recruiting
3
Ankara Medical University
Ankara, Turkey (Türkiye)
Actively Recruiting
4
Gazi University
Ankara, Turkey (Türkiye)
Actively Recruiting
5
Hacettepe University
Ankara, Turkey (Türkiye)
Actively Recruiting
6
Marmara University
Istanbul, Turkey (Türkiye)
Actively Recruiting
7
Necemttin Erbakan University
Konya, Turkey (Türkiye)
Actively Recruiting
Research Team
H
Helen C Su, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here